Please login to the form below

Not currently logged in
Email:
Password:

Noven

This page shows the latest Noven news and features for those working in and with pharma, biotech and healthcare.

Hisamitsu's Noven unit signs Brisdelle deal with Shionogi

Hisamitsu's Noven unit signs Brisdelle deal with Shionogi

Hisamitsu's Noven unit signs Brisdelle deal with Shionogi. Will co-promote the menopausal hot flushes treatment. ... Noven is to co-promote its menopausal hot flushes treatment Brisdelle (paroxetine) with Shionogi.

Latest news

  • Pfizer enters ADHD market with Quillivant XR launch Pfizer enters ADHD market with Quillivant XR launch

    Shire's Daytrana (methylphenidate; now divested to Noven), Vyvanse (lisdexamfetamine) and Intuniv (guanfacine), as well as Johnson &Johnson's Concerta (methylphenidate).

  • Pfizer pays $680m to buy ADHD drug developer NextWave Pfizer pays $680m to buy ADHD drug developer NextWave

    The market in the US has been dominated for some time by Shire - with products such as Daytrana (methylphenidate; now divested to Noven Pharma), Vyvanse (lisdexamfetamine) and Intuniv (guanfacine) - and Johnson

  • News in brief, July 13, 2007

    Noven added that it expected the acquisition to provide an annual sales of over USD 500m beginning in 2012. ... Following closing, Phillip Satow, CEO and co-founder of JDS, may join Noven's board of directors.

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    25+. Noven Therapeutics/ ANI Pharmaceuticals. Acquisition of NDA †. Lithobid (lithium carbonate extended release tablets) for manic-depressive illness (NDA).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics